# AOD-9604: The HGH Fragment That Targets Fat Without the Side Effects
> Note: PeptIQ is not a medical provider. The information in this article is for educational purposes only. Always consult a qualified healthcare professional before starting any peptide protocol.
If you've looked into growth hormone for fat loss but were put off by the glucose disruption, IGF-1 concerns, or carpal tunnel risk — AOD-9604 is worth understanding. It's a synthetic fragment of the HGH molecule, specifically engineered to retain the fat-burning properties of full growth hormone without the metabolic side effects.
It's not a miracle compound. But in a well-designed fat loss stack — particularly alongside a GLP-1 agonist — it earns its place.
What Is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to amino acids 176–191 of human growth hormone. It was developed by Monash University in Australia with the specific goal of isolating HGH's fat-metabolism effects.
Full HGH has two primary mechanisms for fat loss:
- Direct lipolysis — stimulating fat cells to break down stored triglycerides
- Inhibiting fat storage (lipogenesis)
Both of these actions are mediated by the C-terminal end of the HGH molecule — the region that became AOD-9604. The IGF-1 stimulation, glucose effects, and growth-promoting properties come from a different region of HGH.
By isolating the fat-specific fragment, AOD-9604 delivers lipolysis stimulation with a much cleaner safety profile than full HGH.
How AOD-9604 Works
AOD-9604 stimulates fat breakdown through beta-3 adrenergic receptors and HGH receptor partial agonism. The result:
- Increased lipolysis: Fat cells release stored fatty acids for use as fuel
- Inhibited lipogenesis: Dietary fats are less readily converted to stored body fat
- No significant IGF-1 stimulation: Means no growth of existing tumors or cancer risk amplification that concerns some clinicians with full GH
- No significant glucose disruption: Unlike full HGH, which causes insulin resistance at therapeutic doses, AOD-9604 shows minimal glucose impact in studies
This makes it uniquely well-suited for fat loss use cases where full HGH would be too blunt an instrument.
AOD-9604 vs Full HGH: The Key Differences
| Factor | AOD-9604 | Full HGH |
|---|---|---|
| Fat loss mechanism | Direct (HGH 176-191) | Direct + IGF-1 indirect |
| IGF-1 stimulation | Minimal | Significant |
| Glucose impact | Minimal | Insulin resistance at doses >2IU |
| Carpal tunnel / edema | Rare | Common at higher doses |
| Muscle-building effect | Negligible | Yes (via IGF-1) |
| Monitoring required | Minimal | IGF-1, glucose, fasting insulin |
| Cost | Moderate | High |
The bottom line: If your goal is specifically fat loss and body recomposition, AOD-9604 gives you the most targeted tool. If you want muscle gain + fat loss, full HGH or GH secretagogues (CJC-1295 + Ipamorelin) have more to offer.
Dosing Protocol
Standard Research Protocol
Dose: 300mcg per day subcutaneous
Timing: Fasted — ideally 30–60 minutes before eating or exercise
Injection site: Lower abdomen or thigh (standard subQ technique)
Frequency: Daily, or 5 days on / 2 days off
Cycle length: 8–12 weeks, then 4–6 week break
Reconstitution
AOD-9604 dissolves readily in bacteriostatic water (BAC water) — no acetic acid required, unlike some hydrophobic peptides.
Standard reconstitution for a 5mg vial:
- Add 2mL BAC water → 2.5mg/mL (2,500mcg/mL)
- For a 300mcg dose: draw 12 units on an insulin syringe
- Store refrigerated after reconstitution; stable 4–6 weeks
For a 2mg vial:
- Add 1mL BAC water → 2mg/mL (2,000mcg/mL)
- For a 300mcg dose: draw 15 units
Timing Matters
The fasted window is important. AOD-9604 stimulates lipolysis — free fatty acids need somewhere to go. If you dose post-meal with elevated insulin, those fatty acids will be quickly re-esterified back into fat storage. Fasted morning + 20–30 minutes of Zone 2 cardio maximizes the fat mobilization effect.
Stacking AOD-9604 With GLP-1 Agonists
This is where AOD-9604 gets genuinely interesting. GLP-1 agonists (Retatrutide, Tirzepatide, Semaglutide) create a caloric deficit primarily through appetite suppression. AOD-9604 targets the lipolysis side — directly stimulating fat breakdown independent of caloric intake.
The combination works through complementary mechanisms:
GLP-1 agonist → appetite suppression → caloric deficit → forces the body to use stored energy
AOD-9604 → directly stimulates fat cells to release that stored energy + inhibits new fat storage
In practice, users report that AOD-9604 helps address stubborn fat deposits — particularly visceral and lower abdominal fat — that persist even on effective GLP-1 therapy.
Suggested Stack for Fat Loss
| Compound | Dose | Timing |
|---|---|---|
| Retatrutide (or Tirzepatide) | Per titration schedule | Weekly |
| AOD-9604 | 300mcg/day | Fasted AM |
| Tesamorelin (optional add) | 1-2mg/day | Pre-bed or fasted AM |
Tesamorelin (a GHRH analog) adds another layer — it stimulates endogenous GH release, which complements AOD-9604's direct lipolysis. This three-compound stack is particularly effective for targeting visceral fat that's resistant to GLP-1 therapy alone.
Who Is AOD-9604 Best For?
Good candidate if you:
- Are already on a GLP-1 agonist and want to accelerate fat loss
- Want HGH fat-loss benefits without glucose or IGF-1 concerns
- Have a body recomposition goal (not primarily muscle-building)
- Are post-menopausal or have declining GH axis function
- Have stubborn visceral or abdominal fat despite caloric deficit
Less ideal if you:
- Want muscle-building as your primary goal (use CJC+Ipa or full HGH instead)
- Are expecting dramatic standalone results without a caloric deficit
- Are looking for the strength and lean mass effects of GH secretagogues
What to Expect
Weeks 1–2: Minimal visible change. AOD-9604 doesn't create rapid dramatic results. The lipolysis effect is real but cumulative.
Weeks 3–6: Gradual improvement in body composition. Users typically notice the effect in the abdominal and visceral fat regions first. Clothes fit differently before the scale moves significantly.
Weeks 6–12: Cleaner body composition across the whole cycle. When stacked with a GLP-1 agonist, the combined effect is noticeably more pronounced than GLP-1 alone.
Post-cycle: No harsh rebound. No PCT required. The fat-loss benefit persists as long as caloric discipline and training continue.
Side Effects & Safety
AOD-9604 has a genuinely clean safety profile based on both clinical studies and community use:
- Injection site reactions: Mild redness or bruising, common and temporary
- Headache: Reported by a minority of users in the first week, typically self-resolving
- Fatigue: Occasional, especially at higher doses — usually resolves
- No significant hormonal disruption: Unlike full HGH, no thyroid, insulin, or IGF-1 concerns at standard doses
AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient during its development phase — an unusual distinction that reflects its clean clinical safety data.
Frequently Asked Questions
Q: Does AOD-9604 require cycling?
Yes — 8–12 weeks on, then a 4–6 week break. Continuous use may lead to receptor downregulation over time, and cycling preserves the efficacy of each run.
Q: Can I take AOD-9604 without a GLP-1 agonist?
Yes. It works as a standalone fat loss compound. The GLP-1 stack amplifies results, but AOD-9604 is effective on its own, especially when combined with a caloric deficit and Zone 2 cardio.
Q: Will AOD-9604 help with belly fat specifically?
Yes — visceral fat and subcutaneous abdominal fat respond particularly well, consistent with how HGH's fat-metabolism effects work in the literature.
Q: Do I need bloodwork monitoring?
Minimal compared to full HGH. Basic metabolic panel before starting is smart practice. No regular IGF-1 monitoring required (unlike full HGH therapy). If stacking with Tesamorelin, periodic IGF-1 checks are worth doing.
Q: Can I stack AOD-9604 with BPC-157 or TB-500?
Yes — different mechanisms, no interaction concerns. BPC-157/TB-500 is a recovery and tissue repair stack; AOD-9604 is a fat metabolism compound. They run in parallel without issue.
Q: Where do I source AOD-9604?
Quality matters with peptides. Third-party HPLC-verified sources are important. American Peptide Research is a reputable US-based supplier: americanpeptideresearch.net/ref/126
---
Track Your Protocol With PeptIQ
Body recomposition is a long game. The combination of GLP-1 agonists + AOD-9604 works over 8–12+ weeks — not days. PeptIQ helps you log your peptide stack, track weekly measurements and photos, and see the cumulative progress that's easy to lose sight of on a day-to-day basis.
Download PeptIQ — Premium subscription.
